361 related articles for article (PubMed ID: 30111286)
1. Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.
Mahmoudpour SH; Bandapalli OR; da Silva Filho MI; Campo C; Hemminki K; Goldschmidt H; Merz M; Försti A
BMC Cancer; 2018 Aug; 18(1):820. PubMed ID: 30111286
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
3. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis.
Kanbayashi Y; Hosokawa T; Okamoto K; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Taniwaki M
Anticancer Drugs; 2010 Oct; 21(9):877-81. PubMed ID: 20679888
[TBL] [Abstract][Full Text] [Related]
4. A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.
Magrangeas F; Kuiper R; Avet-Loiseau H; Gouraud W; Guérin-Charbonnel C; Ferrer L; Aussem A; Elghazel H; Suhard J; Sakissian H; Attal M; C Munshi N; Sonneveld P; Dumontet C; Moreau P; van Duin M; Campion L; Minvielle S
Clin Cancer Res; 2016 Sep; 22(17):4350-4355. PubMed ID: 27060151
[TBL] [Abstract][Full Text] [Related]
5. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
6. Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci.
Campo C; Da Silva Filho MI; Weinhold N; Goldschmidt H; Hemminki K; Merz M; Försti A
Neurochem Res; 2017 Mar; 42(3):925-931. PubMed ID: 27422265
[TBL] [Abstract][Full Text] [Related]
7. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.
Johnson DC; Corthals SL; Walker BA; Ross FM; Gregory WM; Dickens NJ; Lokhorst HM; Goldschmidt H; Davies FE; Durie BG; Van Ness B; Child JA; Sonneveld P; Morgan GJ
J Clin Oncol; 2011 Mar; 29(7):797-804. PubMed ID: 21245421
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-induced peripheral neuropathy: A genome-wide association study on multiple myeloma patients.
Campo C; da Silva Filho MI; Weinhold N; Mahmoudpour SH; Goldschmidt H; Hemminki K; Merz M; Försti A
Hematol Oncol; 2018 Feb; 36(1):232-237. PubMed ID: 28317148
[TBL] [Abstract][Full Text] [Related]
9. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients.
Johnson C; Pankratz VS; Velazquez AI; Aakre JA; Loprinzi CL; Staff NP; Windebank AJ; Yang P
J Neurol Sci; 2015 Feb; 349(1-2):124-8. PubMed ID: 25586538
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
[TBL] [Abstract][Full Text] [Related]
11. Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study.
Hooshmand K; Goldstein D; Timmins HC; Li T; Harrison M; Friedlander ML; Lewis CR; Lees JG; Moalem-Taylor G; Guennewig B; Park SB; Kwok JB
J Transl Med; 2022 Dec; 20(1):564. PubMed ID: 36474270
[TBL] [Abstract][Full Text] [Related]
12. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.
García-Sanz R; Corchete LA; Alcoceba M; Chillon MC; Jiménez C; Prieto I; García-Álvarez M; Puig N; Rapado I; Barrio S; Oriol A; Blanchard MJ; de la Rubia J; Martínez R; Lahuerta JJ; González Díaz M; Mateos MV; San Miguel JF; Martínez-López J; Sarasquete ME;
Hematol Oncol; 2017 Dec; 35(4):746-751. PubMed ID: 27605156
[TBL] [Abstract][Full Text] [Related]
13. Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors.
Thomaier L; Darst BF; Jewett P; Hoffmann C; Brown K; Makaram A; Blaes A; Argenta P; Teoh D; Vogel RI
Gynecol Oncol; 2021 Dec; 163(3):578-582. PubMed ID: 34674889
[TBL] [Abstract][Full Text] [Related]
14. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.
Terrazzino S; Argyriou AA; Cargnin S; Antonacopoulou AG; Briani C; Bruna J; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP; Canonico PL; Genazzani AA; Cavaletti G
J Peripher Nerv Syst; 2015 Mar; 20(1):15-23. PubMed ID: 25858589
[TBL] [Abstract][Full Text] [Related]
15. Identification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial.
Lustberg M; Wu X; Fernández-Martínez JL; de Andrés-Galiana EJ; Philips S; Leibowitz J; Schneider B; Sonis S
Support Care Cancer; 2023 Jan; 31(2):139. PubMed ID: 36707490
[TBL] [Abstract][Full Text] [Related]
16. Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional study.
Giraudet F; Selvy M; Kerckhove N; Pereira B; Barreau F; Nguyen D; Busserolles J; Cabrespine A; Chaleteix C; Soubrier M; Bay JO; Lemal R; Balayssac D
Eur Arch Otorhinolaryngol; 2022 Apr; 279(4):2197-2201. PubMed ID: 35098333
[TBL] [Abstract][Full Text] [Related]
17. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.
Chan A; Hertz DL; Morales M; Adams EJ; Gordon S; Tan CJ; Staff NP; Kamath J; Oh J; Shinde S; Pon D; Dixit N; D'Olimpio J; Dumitrescu C; Gobbo M; Kober K; Mayo S; Pang L; Subbiah I; Beutler AS; Peters KB; Loprinzi C; Lustberg MB
Support Care Cancer; 2019 Oct; 27(10):3729-3737. PubMed ID: 31363906
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel.
Ventzel L; Jensen AB; Jensen AR; Jensen TS; Finnerup NB
Pain; 2016 Mar; 157(3):560-568. PubMed ID: 26529271
[TBL] [Abstract][Full Text] [Related]
19. The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry.
Beijers AJ; Oerlemans S; Mols F; Eurelings M; Minnema MC; Vreugdenhil A; van de Poll-Franse LV
Ann Hematol; 2017 Apr; 96(4):653-663. PubMed ID: 28116479
[TBL] [Abstract][Full Text] [Related]
20. Adhesive capsaicin 8% patch for improved control of pain caused by chemotherapy-induced peripheral neuropathy in patients with multiple myeloma: A single-centre, seven-case series.
Moreno-Alonso D; Llorens-Torromé S; Corcoy de Febrer B; Amandi García M; Serrano-Bermúdez G; Trelis-Navarro J; Mayoral-Rojals V; Serrano-Afonso A
J Oncol Pharm Pract; 2024 Jun; 30(4):752-758. PubMed ID: 38415287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
